DISEASE SCANNER
Global Incurable Diseases Tracker
Attention-Deficit/Hyperactivity Disorder (ADHD)
A neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. Begins in childhood and often persists into adulthood. Affects approximately 5-7% of children and 2.5-4% of adults globally. Three subtypes: predominantly inattentive, predominantly hyperactive-impulsive, and combined.
366.0M
111
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Clinical interview (DSM-5 criteria)
- 2ADHD rating scales
- 3Conners scales
- 4Continuous performance tests
- 5Teacher/parent reports
- 6Neuropsychological testing
- 7Rule out other conditions
Prognosis
50-60% continue to have symptoms into adulthood. With treatment: improved academic/work performance, reduced accidents, better relationships. Untreated: increased risk of substance abuse, accidents, unemployment, relationship problems.
Prevention
- No proven prevention
- Prenatal care
- Avoiding prenatal substance exposure
- Early intervention
- Behavioral parent training
Research Status
Stimulants (methylphenidate, amphetamines) remain first-line. Non-stimulants (atomoxetine, guanfacine) alternatives. Long-acting formulations improving adherence. Digital therapeutics (EndeavorRx) FDA-approved. Neurofeedback research ongoing. Gene therapy not yet applicable but genetic research advancing.
Affected Countries
Sources
- https://www.psychiatry.org
- https://www.cdc.gov/
- https://www.hematology.org/education/patients
- https://www.ncbi.nlm.nih.gov/books
- https://rarediseases.org/rare-diseases
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.